Base&Byte Biotechnology

Base&Byte Biotechnology is an AI-driven biotechnology company headquartered in Beijing, China, specializing in the discovery and development of macromolecule drugs and personalized cancer therapies. Founded in 2021, the company leverages its proprietary "Neo" suite of platforms—including NeoTarget for target identification, NeoBody for antibody and peptide design, and NeoDesign for tumor neoantigen prediction—to accelerate drug development. Base&Byte integrates high-throughput wet-lab validation (NeoHTS) with advanced deep learning algorithms, such as Transformer and diffusion models, to address elusive drug targets. The company has established strategic partnerships with industry leaders like Alibaba Cloud and NVIDIA and has seen its neoantigen platform implemented in investigator-initiated clinical trials at top-tier hospitals. Its research also extends to innovative delivery and adjuvant technologies, such as the FcRider nanoparticle platform for hybrid immunization.